Skip to content
Evigrade
ModerateVitamin K antagonist anticoagulants×Antifungals, triazole derivatives

Updated · Methodology

Mechanism

In the liver, CYP2C9 is the main enzyme that metabolises acenocoumarol, and CYP1A2 and CYP2C19 also metabolise its more active R-enantiomer (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Fluconazole moderately inhibits CYP2C9 and CYP3A4 and strongly inhibits CYP2C19. Because of its long half-life, its effect on these enzymes persists for 4–5 days after fluconazole is stopped (fluconazole SmPC, AEMPS). The Spanish SmPC of a generic acenocoumarol explicitly names fluconazole among drugs that can potentiate acenocoumarol (acenocoumarol SmPC, AEMPS). The documents give no figures for acenocoumarol, and data exist only for warfarin. With warfarin plus fluconazole, the prothrombin time lengthened up to 2-fold, probably because fluconazole inhibits warfarin metabolism through CYP2C9 (fluconazole SmPC, AEMPS).

Symptoms

The main risk is bleeding. With fluconazole and warfarin, post-marketing reports described bleeding with a prolonged prothrombin time: bruising, nosebleeds, gastrointestinal bleeding, blood in the urine and black stools (fluconazole summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Acenocoumarol can cause serious bleeding, including haemorrhagic shock, and fatal bleeding. The risk is higher with an international normalised ratio (INR) above 4.0, at age 65 or older and with concomitant treatment (acenocoumarol SmPC, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, vomiting blood, uterine bleeding, nosebleeds, bleeding gums and bleeding into joints. Fast heartbeat, low blood pressure, nausea, vomiting, diarrhoea and abdominal pain may follow (AEMPS).

Management

The combination is not contraindicated but needs frequent coagulation monitoring. When combining fluconazole with coumarin-type anticoagulants, which include acenocoumarol, monitor the prothrombin time carefully (fluconazole summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; fluconazole prescribing information, US Food and Drug Administration, FDA). These labels discuss dose adjustment only for warfarin. The acenocoumarol SmPCs ask for close and frequent coagulation checks, for example twice a week, both when another drug is added and when it is stopped (acenocoumarol SmPCs, AEMPS). The effect of fluconazole on the enzymes persists for 4–5 days after fluconazole is stopped (fluconazole SmPC, AEMPS). A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. In patients outside the target range, the effect of a dose change is usually assessed after 7–8 days. Base dose adjustments on the total weekly dose, spread as evenly as possible over seven days (acenocoumarol SmPC, AEMPS). With an international normalised ratio (INR) below 4.5 and minor bleeding, such as a short nosebleed or small isolated bruises, temporarily reducing or skipping a dose is often enough. With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, interrupt it and give 1–5 mg of vitamin K1 by mouth (AEMPS). In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute. In severe bleeding, replace clotting factors with fresh whole blood, prothrombin complex concentrate or recombinant factor VIIa together with vitamin K1 (AEMPS). After bleeding, restart acenocoumarol once the INR is back in the target range (AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Acenocoumarol

Other interactions with Fluconazole